Corporate Overview

We are an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. We launched the iStent®, our first MIGS device, in the United States in 2012, our next-generation iStent inject® device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, our proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. We are leveraging our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Read more

Latest News

View all news

Latest Presentation

Latest Events

View All Events